Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Cardiomyopathies market size was approximately $1.6 billion across the 7MM in 2021. The market is expected to grow at a CAGR of more than 12% during the forecast period. The US is the most significant contributor to that revenue.
Cardiomyopathies Market Outlook
For more insights on cardiomyopathies market forecast, download a free sample
What are the major drivers of the cardiomyopathies market?
Major drivers of the cardiomyopathies market during the forecast period include Camzyos’ market launch as the first drug to target obstructive HCM and the launch of Aficamten. Aficamten is a drug with the same mechanism of action as Camzyos, which should more closely target the pathophysiology of cardiomyopathy. Entresto’s label expansion to include cardiomyopathy, although the drug is already used globally off-label to manage the disease. There are improvements in genetic screening and genetic therapy options.
Which are the key countries in the cardiomyopathies market?
The key countries in the cardiomyopathies market are the US, France, Germany, Italy, the UK, Spain and Japan. The US has the highest sales in the cardiomyopathies market.
Cardiomyopathies market, by key countries
For more country insights, download a free report sample
What are the key subtypes in the Cardiomyopathies market?
The key subtypes in the Cardiomyopathies market are DCM, HCM, RCM, and ARCM. In 2021, DCM and HCM were the most common cardiomyopathy subtypes in the 7MM.
Cardiomyopathies market, by subtypes
For more subtype insights, download a free report sample
Diagnosed Prevalent Cases of Cardiomyopathies by Etiology
The two segments in the diagnosed prevalent cases of cardiomyopathies by etiology are acquired and familial. The most diagnosed cases of cardiomyopathies in the 7MM were acquired in 2021.
Cardiomyopathies market, by etiology
For more etiology insights, download a free report sample
Diagnosed Prevalent Cases of Dilated Cardiomyopathy by Ischemia
The two key segments in the diagnosed prevalent cases of cardiomyopathies by ischemia are Ischemic and non-ischemic. In 2021, most diagnosed DCM cases in the 7MM were non-ischemic.
Cardiomyopathies market, by Ischemia
For more Ischemia insights, download a free report sample
Market report overview
Market size 2021 | $1.6 billion |
CAGR % | 12% |
Key countries | The US, France, Germany, Italy, The UK, Spain and Japan |
Key subtypes | DCM, HCM, RCM, and ARCM |
Key etiology | Acquired and Familial |
Key Ischemia | Ischemic and Non-Ischemic |
Scope
- Overview of cardiomyopathies including epidemiology, disease etiology and management.
- Topline cardiomyopathy drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global cardiomyopathy therapeutics market. Insightful review of the key industry drivers, restraints and challenges.
Key Highlights
The cardiomyopathies market is currently highly genericized and contains many off-label medications, which provide affordable options with limited side effects. These factors create a stiff barrier for entry of novel therapeutics, but pipeline therapeutics will find success due to strong efficacy and safety profiles and that they are cardiomyopathy-specific therapeutics, rather than general cardiovascular drugs.
There is an increased focus on genetic screening and developing genetic therapeutics because cardiomyopathies are often inherited rather than acquired. Emprumapimod will be the first marketed genetic therapy, as it targets patients with DCM due to a lamin gene mutation. However, this drug will not generate significant revenue given the small size of the target patient population.
There is not a cure for cardiomyopathies, instead the disease symptoms are managed with generic cardiovascular drugs. This remains an area of unmet need in the cardiomyopathies space.
Camzyos was the first novel therapy launched in the cardiomyopathies market in several decades when it was marketed in 2022. Thus, there is a need for novel therapies in this space, which should be met by the extensive pipeline.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global cardiomyopathy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cardiomyopathies market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global cardiomyopathy therapeutics market from 2021-2031.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Merck
Boehringer Ingelheim
Novartis
Sanofi
Abbott
GlaxoSmithKline
Bristol Myers Squibb
MyoKardia
Pfizer
Cytokinetics
Table of Contents
Table
Figures
Frequently asked questions
-
What was the Cardiomyopathy market size in the year 2021 across 7MM?
The Cardiomyopathy market was valued at $1.6 billion in the year 2021 across 7MM.
-
What was the Cardiomyopathy market growth rate?
The Cardiomyopathy market is expected to grow at a CAGR of more than 12%.
-
Which are the key countries in the cardiomyopathies market?
The key countries in the cardiomyopathies market are the US, France, Germany, Italy, the UK, Spain and Japan.
-
What are the key subtypes in the Cardiomyopathies market?
The key subtypes in the Cardiomyopathies market are DCM, HCM, RCM, and ARCM.
-
What are the key segments in etiology in the cardiomyopathies market?
The key segments in etiology in the cardiomyopathies market are acquired and familial.
-
What are the key segments of Ischemia in the cardiomyopathies market?
The key segments of Ischemia in the cardiomyopathies market are ischemic and non-ischemic
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.